Albrecht K.,Deutsches Rheuma Forschungszentrum Berlin
Deutsche Medizinische Wochenschrift | Year: 2014
Patients with rheumatoid arthritis (RA) often have one or more comorbid conditions. The prevalence of comorbidities increases with age and disease duration. Comorbidities influence the outcome of RA and limit therapeutic options. Besides suppressing disease activity of RA, screening and tight control of existing comorbidities is essential to avoid further damage. A close cooperation between general practitioners, rheumatologists and attending specialists is important for a successful treatment, taking into account the complex interaction of RA and its comorbidities. Source
Agency: Cordis | Branch: FP7 | Program: MC-IEF | Phase: FP7-PEOPLE-2012-IEF | Award Amount: 168.79K | Year: 2013
More than 5 million people in Europe live with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). Both diseases are characterized by chronic inflammation partially mediated by inappropriate T cell response. Effector T-cell responses can be modulated by competing positive or negative costimulatory signals, and dysregulated balance between these signals may lead to chronic autoimmune inflammation. In mice, within the CD4\ T cell population, the expression of NKG2D is primarily associated with pathological conditions and the administration of blocking anti-NKG2D antibodies ameliorated the disease in mouse models of arthritis and IBD. Therefore the aim of my project proposal is to clarify the role of NKG2D receptor signalling in CD4\ T cell biology and in the pathogenesis of autoimmune diseases. My work will implement mouse models to study the specific impact of NKG2D expressed on CD4\ T cells in the priming, formation and maintainance of memory of CD4\ T cells and their cytokine profile during homeostasis as well as in preclinical models of IBD and RA. Moreover, by global analysis of human NKG2D\ CD4\ T cells from the sites of inflammation, we aim to better understand the possible role of NKG2D in driving inflammatory responses in IBD and RA patients. By combining these approaches, we intend to get further insights into the role of NKG2D in the regulation of autoimmune diseases and to identify strategies to possibly ameliorate tissue damage and dampen inflammation.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2010.4.2-3 | Award Amount: 3.92M | Year: 2011
Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other serious diseases with chronic inflammation were limited. Advances in understanding the pathophysiology of the inflammatory responses have led to the development of a new class of medications that are capable of inhibiting selectively the principal mediators of inflammation and tissue damage. The introduction of these new immunomodulators, which are collectively termed biologics, has opened a new era in the treatment of inflammatory diseases. Recent reports however suggest unexpected increases in adverse - or serious events -associated with the use of these biologics. PHARMACHILD aims to detect, assess and understand long term and short term side effects of the use of biologics by studying the pharmacovigilance in a large international cohort of patients with Juvenile Idiopathic Arthritis (children and young adults) in order to support regulatory decisions on marketing authorizations for these products. There is a clear need for a study that will enable the promotion of more effective and safer use of biologics in JIA as children and young adolescents represent an especially vulnerable patient group, JIA is the most common chronic disease of childhood treated with biologics, and data available from adults cannot be extrapolated to children. PHARMACHILD brings together leading European scientists in the field of infectious diseases, immunity, inflammation and oncology. Our network combines resources from international organizations and existing national registries. This combination will enable us to achieve the critical mass (in terms of expertise and resources) to identify the risk factors for developing adverse events, to elucidate the mechanisms involved in the adverse events (such as latent infection reactivation) and to develop methodologies for screening and predicting patients at risk.
Deutsches Rheuma Forschungszentrum Berlin | Date: 2011-10-12
The invention relates to a system for acquiring discontinuous emission spectra data, whereby the data is analyzed by a multivariate statistic model or equivalent model, such as principal component analysis and the use of the system for flow cytometry.
Deutsches Rheuma Forschungszentrum Berlin | Date: 2010-02-16
The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells.